Rheumatoid arthritis Trials in Caba., Argentina
Conditions / Rheumatoid arthritis / Caba., Argentina
Clinical trials for Rheumatoid arthritis investigate a range of treatment strategies and patient populations.
18 total trials for this combination
Showing top 10 of 18 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01709578 | To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) | COMPLETED | PHASE3 |
| NCT01061736 | Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients | COMPLETED | PHASE2/PHASE3 |
| NCT01146652 | Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND) | COMPLETED | PHASE3 |
| NCT01885078 | An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT01711359 | A Study in Participants With Moderate to Severe Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT05516758 | A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis | TERMINATED | PHASE2 |
| NCT02886728 | Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy | COMPLETED | PHASE3 |
| NCT01377012 | Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents | COMPLETED | PHASE3 |
| NCT01710358 | A Study in Moderate to Severe Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT02889796 | Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate | COMPLETED | PHASE3 |